WO2011052884A2 - 테오브로민 함유 서방성 정제 - Google Patents
테오브로민 함유 서방성 정제 Download PDFInfo
- Publication number
- WO2011052884A2 WO2011052884A2 PCT/KR2010/005911 KR2010005911W WO2011052884A2 WO 2011052884 A2 WO2011052884 A2 WO 2011052884A2 KR 2010005911 W KR2010005911 W KR 2010005911W WO 2011052884 A2 WO2011052884 A2 WO 2011052884A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- theobromine
- release layer
- sustained
- release
- weight
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Definitions
- the present invention relates to a theobromine-containing sustained-release tablet, which will be described in more detail, comprising 40-60% by weight of the active ingredient theobromine and 14-19% by weight of a sustained-release base composed of polyethylene oxide and hydroxypropyl methylcellulose.
- a rapid release layer comprising a sustained release layer, and disintegrant 0.5-2% by weight consisting of 10-30% by weight of the active ingredient, theobromine and one or two selected from sodium croscarmellose, crospovidone, and sodium starch glycolate. It is composed of layers, and relates to theobromine-containing sustained-release tablets that can effectively improve various cough symptoms by taking only once daily.
- cough is a common human defense that is seen in healthy people, but cough caused by various diseases greatly worsens the quality of life.
- antitussives such as codeine (drug) and dextrometropan are widely used, but these antitussive components have various side effects on the central nervous system while acting on the central nervous system.
- Theobromine suppresses coughing by peripherally suppressing the vagus nerve excitability of the bronchial or pulmonary end that causes pharmacological cough.
- Theobromine is the main component of cocoa, such as caffeine and theophylline, alkaloid methylxanthine-based drugs, but unlike caffeine and theophylline, there is little excitement for the central nervous system.
- theobromine is non-narcotic and acts on the peripheral nervous system.
- Korean Patent Publication No. 10-2001-5642 (published date 2001.01.15.) Describes the pharmacological effect of theobromine cough in detail.
- theobromine is about 4 times higher in antitussive treatment index than codeine, a powerful antitussive ingredient, while introducing side effects as much safer than other antitussive ingredients.
- Korean Patent Publication No. 10-2008-9994 (published date 2008.01.30.) Discloses a composition for treating cough using a theobromine compound.
- a composition for treating cough using a theobromine compound As a result of conducting a clinical trial with a capsule prepared with a therapeutic composition containing theobromine compound, it has been shown to have an effect of significantly alleviating cough symptoms, and there is no specificity in the occurrence of adverse reactions. It has been reported to effectively relieve cough symptoms caused by causative diseases such as postnasal fistula and gastroesophageal reflux.
- theobromine capsules disclosed in Korean Patent Application Publication No. 10-2008-9994 have a disadvantage in that the drug release time is so fast that the drug must be taken at least twice a day for effective cough treatment.
- the drug does not maintain the effective blood concentration, the symptoms of coughing does not improve, and as a result, the treatment period is prolonged.
- the problem to be solved by the present invention is to provide a theobromine-containing sustained-release tablet that can maintain an immediate and effective effective blood concentration even once a day.
- theobromine-containing sustained-release tablet according to the present invention is 40-60% by weight of theobromine or a salt thereof, 14-19% by weight of a sustained-release base composed of polyethylene oxide and hydroxypropyl methylcellulose, and binder 1
- a sustained release layer comprising 2 wt% and 0.5-1 wt% of a lubricant; 10 to 30% by weight of theobromine or its salt, 0.5 to 2% by weight of a disintegrant consisting of one or two or more selected from croscarmellose sodium, crospovidone, and sodium starch glycolate, and 0.3 to 1.5% by weight of a binder,
- a quick release layer comprising 0.1 to 0.5% by weight of a lubricant; Characterized in that consists of.
- the content of theobromine or salt thereof included in the sustained release layer and the rapid release layer is 300 mg or 600 mg in total.
- the sustained-release base is characterized in that consisting of 6 to 10% by weight of polystyrene oxide having a molecular weight of 900,000 to 1,000,000, and 8 to 12% by weight of hydroxypropyl methylcellulose having a viscosity of 4000cp.
- the sustained release layer and the rapid release layer may be a two-layer structure stacked up or down, or a three-layer structure in which the rapid release layer is laminated on the upper and lower layers, respectively, using the sustained release layer as a center layer.
- Theobromine-containing sustained-release tablet according to the present invention can immediately express the initial effect after taking the active ingredient in the immediate release layer, and the active ingredient is continuously released in the sustained-release layer, so the active ingredient is effective in the blood for more than 24 hours.
- the concentration can be maintained. Therefore, taking only once a day has the effect that can effectively improve the various cough symptoms.
- FIG. 1 is a graph showing the elution profile of the sustained-release tablet prepared according to Examples 1-5,
- Figure 2 is a graph showing the dissolution profile of the sustained release tablet prepared according to Examples 6-10.
- Theobromine-containing sustained-release tablet according to the present invention is composed of a sustained release layer and a rapid release layer, wherein the sustained release layer is 40 to 60% by weight of theobromine or its salt, 14 to 19% by weight of the sustained release base, and a binder 1 ⁇ . 2 wt%, 0.5-1 wt% of a lubricant, and the immediate release layer comprises 10-30 wt% of theobromine or its salt, 0.5-2 wt% of the disintegrant, and 0.3-1.5 wt% of the binder. It comprises 0.1 to 0.5% by weight of lubricant.
- theobromine the active ingredient
- theobromine may be in the form of theobromine free base or in the form of a pharmaceutically acceptable salt of theobromine.
- the content of theobromine is preferably about 65% to 75% by weight based on the total weight of the sustained-release tablet is included 300 or 600 mg per tablet.
- Theobromine content of 300 mg per tablet can be taken once a day for 2 tablets once a day, 600 mg can be taken once a day once a tablet.
- the relative content ratio of theobromine included in the sustained release layer is less than 40% by weight or more than 60% by weight, the amount of the active ingredient released after 12 hours after taking it is not good because it is too small or too much, If the relative content ratio of theobromine contained in the emitting layer is less than 10% by weight or more than 30% by weight, the initial release amount of the active ingredient may be too small or too large to maintain the desired release pattern.
- the sustained-release base which is a feature of the present invention, comprises a polyethylene oxide and hydroxypropyl methylcellulose, and its content is 14 to 19% by weight.
- the content of the sustained-release base is less than 14% by weight, the rapid release occurs so that it may not have a desired sustained release function.On the contrary, if the content of the sustained-release base is more than 18% by weight, the disintegration may be delayed, resulting in an extracorporeal discharge through bowel movement. .
- Polyethylene oxide it is preferable to use Polyox TM having a molecular weight of 900,000 (DOW Chemical Company, NF Grades: WSR-1105 NF) or Polyox TM having a molecular weight of 1,000,000 (NF Grades: WSR N-12K NF), and the hydroxypropyl Methyl cellulose is preferably used having a viscosity of 4000cp.
- the disintegrant is made of any one or two or more selected from croscarmellose sodium, crospovidone, sodium starch glycolate, the content is preferably 0.5 to 2% by weight.
- the content of the disintegrant is not technically significant, but if it is less than 0.5% by weight or more than 2% by weight, the disintegration rate of the immediate release layer is too slow or conversely too fast is not preferable.
- the sustained release layer and the immediate release layer each comprise a binder and a lubricant.
- the binder and the lubricant may be any one of those commonly used, but as the binder, any one or two or more of hydroxypropyl cellulose, copovidone, methyl cellulose and gelatin may be used, and the lubricant may be hard. Any one or more of silicic anhydride, talc, magnesium stearate can be used.
- the sustained release layer preferably contains 1 to 2 wt% of a binder and 0.5 to 1 wt% of a lubricant
- the rapid release layer preferably includes 0.3 to 1.5 wt% of a binder and 0.1 to 0.5 wt% of a lubricant.
- Each of the sustained release layer and the rapid release layer may further include an excipient such as di-mannitol, lactose, or microcrystalline cellulose, and may include various colorants as necessary. The content of the excipient and the colorant may be appropriately adjusted as necessary.
- the sustained-release layer composition and the rapid-release layer composition are first prepared by the wet method at the composition ratio as described above, and the sustained-release layer and the rapid-release layer are prepared using a conventional tableting machine. Prepare laminated tablets.
- the tablet may be prepared as a two-layer tablet in which the sustained release layer and the rapid release layer are stacked up and down, the middle layer may be a slow release layer, and the upper and lower layers may be prepared as a three-layer tablet consisting of the rapid release layer.
- the active substance is mixed with theobromine and microcrystalline cellulose as an excipient, and added to the hydroxypropyl cellulose to perform a wet granulation process, the granules After drying, it is stipulated, and the cross release layer sodium stearate and magnesium stearate are mixed to prepare a rapid release layer composition.
- theobromine as the active material microcrystalline cellulose and hydroxypropyl methyl cellulose are mixed, and a binder liquid consisting of hydroxypropyl cellulose is added thereto to form a wet solution.
- the granules are dried and granulated, and polystyrene oxide and magnesium stearate are mixed thereto to prepare a sustained release layer composition.
- the rapid release layer composition and the sustained release layer composition are compressed using a conventional tableting machine.
- tableting a two-layer type tablet in which the rapid release layer and the sustained release layer were stacked up and down
- the intermediate layer was the sustained release layer and the upper and lower layers were the rapid release layer.
- It is made of a three-layer tablet consisting of, and then coated with a conventional film coating base thereon to complete the sustained-release tablet for oral administration.
- Example 8 to 10, Example 3, Example 6 and Example 7 are different only in the laminated structure, respectively, the configuration of the fast-release composition and the sustained-release composition is the same.
- Example 1 was included 600 mg of theobromine active ingredient, Examples 2 to 10 to 300 mg.
- the sustained-release tablets prepared according to Examples 1 to 10 were subjected to a disintegration test according to the disintegration test method of the Korean Pharmacopoeia General Test Method, and the results are shown in Table 4 below.
- theobromine 300mg capsules (trade name; Anycope Capsule, Ankook Drug), which are currently commercially available, were used.
- the sustained-release tablets prepared according to the present invention were found to be suitable for sustained-release preparations by having a significantly later disintegration time than the comparative example.
- the two-layer tablets of Example 3, Example 6, and Example 7 were respectively compressed into three-layer tablets, and despite the difference in structure, there was no change in disintegration time between the two. Shows that
- Comparative dissolution test was performed on the sustained release tablets prepared according to Examples 1 to 10, and the results are shown graphically in Appendix 1 and FIG. 2. At this time, the eluate of pH 6.8 was used as paddle-50rpm by the comparative dissolution test method of the drug equivalence criteria.
- the theobromine-containing sustained-release tablet prepared according to the present invention can be confirmed that the release concentration increases up to 24 hours by controlling the rapid release of the drug over time and enabling continuous release have.
- similar dissolution profiles are exhibited regardless of the two-layer or three-layer structure.
- theobromine-containing sustained release tablet prepared according to the present invention can immediately express the initial effect after taking the active ingredient in the immediate release layer, and the active ingredient is continuously released in the sustained release layer. Effective blood levels can be maintained for more than 24 hours.
- the sustained release tablet of the present invention can effectively improve various cough symptoms by taking only once daily.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
구 분 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | |||||
속방출층 | 서방출층 | 속방출층 | 서방출층 | 속방출층 | 서방출층 | 속방출층 | 서방출층 | ||
테오브로민(활성성분) | 27.7 | 46.2 | 29.8 | 44.7 | 11.6 | 58.1 | 13.2 | 57.0 | |
미결정셀룰로오스(부형제) | 6.3 | 6.0 | 7.8 | 7.6 | |||||
히드록시프로필셀룰로오스(결합제) | 1.1 | 1.4 | 1.2 | 1.3 | 0.5 | 1.7 | 0.5 | 1.7 | |
스테아르산마그네슘(활택제) | 0.5 | 0.7 | 0.5 | 0.7 | 0.2 | 0.9 | 0.2 | 0.9 | |
크로스카멜로오스나트륨(붕해제) | 1.4 | 1.5 | 0.6 | 0.7 | |||||
히드록시프로필메칠셀룰로오스(서방성기제) | 8.5 | 8.3 | 10.8 | 10.5 | |||||
폴리에칠렌옥시드(서방성기제) | WSR 1105NF | 6.2 | 6.0 | 7.8 | 7.7 | ||||
WSR N-12KNF |
구 분 | 실시예 5 | 실시예 6 | 실시예 7 | ||||
속방출층 | 서방출층 | 속방출층 | 서방출층 | 속방출층 | 서방출층 | ||
테오브로민(활성성분) | 11.1 | 55.5 | 11.8 | 58.9 | 11.7 | 58.5 | |
미결정셀룰로오스(부형제) | 4.4 | 7.5 | 7.8 | 7.8 | |||
히드록시프로필셀룰로오스(결합제) | 0.4 | 1.7 | 0.5 | 1.8 | 0.5 | 1.8 | |
스테아르산마그네슘(활택제) | 0.2 | 0.8 | 0.2 | 0.9 | 0.2 | 0.9 | |
크로스카멜로오스나트륨(붕해제) | 0.6 | 0.6 | 0.6 | ||||
히드록시프로필메칠셀룰로오스(서방성기제) | 10.3 | 10.9 | 10.8 | ||||
폴리에칠렌옥시드(서방성기제) | WSR 1105NF | 7.5 | 3.9 | ||||
WSR N-12KNF | 6.6 | 3.3 |
구 분 | 실시예 8 | 실시예 9 | 실시예 10 | |||||||
속방출상층 | 서방출중층 | 속방출하층 | 속방출상층 | 서방출중층 | 속방출하층 | 속방출상층 | 서방출중층 | 속방출하층 | ||
테오브로민 | 5.8 | 58.1 | 5.8 | 5.9 | 58.9 | 5.9 | 5.85 | 58.5 | 5.85 | |
미결정셀룰로오스 | 7.8 | 7.8 | 7.8 | |||||||
히드록시프로필셀룰로오스 | 0.25 | 1.7 | 0.25 | 0.25 | 1.8 | 0.25 | 0.25 | 1.8 | 0.25 | |
스테아르산마그네슘 | 0.1 | 0.9 | 0.1 | 0.1 | 0.9 | 0.1 | 0.1 | 0.9 | 0.1 | |
크로스카멜로오스나트륨 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | ||||
히드록시프로필메칠셀룰로오스 | 10.8 | 10.9 | 10.8 | |||||||
폴리에칠렌옥시드 | WSR 1105NF | 7.8 | 3.9 | |||||||
WSR N-12KNF | 6.6 | 3.3 |
구분 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | 실시예 6 | 실시예 7 | 실시예 8 | 실시예 9 | 실시예 10 | 비교예 |
붕해시간 | 10시간 29분 | 7시간 47분 | 8시간 21분 | 8시간 15분 | 8시간 25분 | 8시간 24분 | 8시간19분 | 8시간18분 | 8시간 29분 | 8시간 27분 | 4분이내 |
Claims (4)
- 테오브로민 또는 그 염 40~60 중량%와, 폴리에칠렌옥시드 및 히드록시프로필 메칠셀룰로오스로 이루어진 서방형 기제 14~19 중량%와, 결합제 1~2 중량%와, 활택제 0.5~1 중량%를 포함하여 이루어지는 서방출층과;테오브로민 또는 그 염 10~30 중량%와, 크로스카멜로오스나트륨, 크로스포비돈, 전분글리콘산나트륨 중에서 선택된 어느 하나 또는 둘 이상으로 이루어진 붕해제 0.5~2 중량%와, 결합제 0.3~1.5 중량%와, 활택제 0.1~0.5 중량%를 포함하여 이루어지는 속방출층; 으로 이루어지는 것을 특징으로 하는 테오브로민 함유 서방성 정제
- 제1항에 있어서, 상기 서방출층과 속방출층에 포함된 테오브로민 또는 그 염의 함량은 합하여 300 mg 또는 600 mg 인 것을 특징으로 하는 테오브로민 함유 서방성 정제
- 제1항 또는 제2항에 있어서, 상기 서방형 기제는 분자량이 900,000 내지 1,000,000인 폴리에칠렌옥시드 6~10 중량%와, 점도가 4000cp인 히드록시프로필 메칠셀룰로오스 8~12 중량%로 이루어진 것을 특징으로 하는 테오브로민 함유 서방성 정제
- 제1항 또는 제2항에 있어서, 상기 서방출층과 속방출층은 상하로 적층된 2층 구조 이거나, 또는 서방출층을 중간층으로 하여 그 상층 및 하층에 각각 속방출층이 적층된 3층 구조로 이루어진 것을 특징으로 하는 테오브로민 함유 서방성 정제
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080051266.9A CN102711740B (zh) | 2009-11-02 | 2010-09-01 | 含可可碱的缓释锭剂 |
BR112012010325A BR112012010325B8 (pt) | 2009-11-02 | 2010-09-01 | comprimido com liberação sustentada e imediata de teobromina |
RU2012119070/15A RU2506947C2 (ru) | 2009-11-02 | 2010-09-01 | Таблетка пролонгированного высвобождения, содержащая теобромин |
UAA201206606A UA103558C2 (ru) | 2009-11-02 | 2010-09-01 | Таблетка пролонгированного высвобождения, которая содержит теобромин |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0105137 | 2009-11-02 | ||
KR1020090105137A KR101137467B1 (ko) | 2009-11-02 | 2009-11-02 | 테오브로민 함유 서방성 정제 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011052884A2 true WO2011052884A2 (ko) | 2011-05-05 |
WO2011052884A3 WO2011052884A3 (ko) | 2011-07-14 |
Family
ID=43922740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/005911 WO2011052884A2 (ko) | 2009-11-02 | 2010-09-01 | 테오브로민 함유 서방성 정제 |
Country Status (7)
Country | Link |
---|---|
KR (1) | KR101137467B1 (ko) |
CN (1) | CN102711740B (ko) |
BR (1) | BR112012010325B8 (ko) |
RU (1) | RU2506947C2 (ko) |
TR (1) | TR201205029T1 (ko) |
UA (1) | UA103558C2 (ko) |
WO (1) | WO2011052884A2 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101220830B1 (ko) * | 2010-08-18 | 2013-01-10 | 안국약품 주식회사 | 테오브로민의 서방성 과립제 및 그 제조방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060113728A (ko) * | 2003-11-13 | 2006-11-02 | 룀 게엠베하 | 조절 물질의 전달에 영향을 미치는 매트릭스를 갖는 다층약제학적 형태 |
KR20070017335A (ko) * | 2004-03-22 | 2007-02-09 | 노파르티스 아게 | 리카르바제핀을 포함하는 경구투여용 매트릭스 제제 |
KR20070078625A (ko) * | 2006-01-27 | 2007-08-01 | 씨제이 주식회사 | 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법 |
KR20070119658A (ko) * | 2005-03-29 | 2007-12-20 | 에보니크 룀 게엠베하 | 활성 성분 방출에 대한 조절 효과를 가지는 물질을포함하는 펠렛을 포함하는 다중 미립자 제약 형태 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196481A1 (en) * | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
-
2009
- 2009-11-02 KR KR1020090105137A patent/KR101137467B1/ko active IP Right Grant
-
2010
- 2010-09-01 RU RU2012119070/15A patent/RU2506947C2/ru active
- 2010-09-01 CN CN201080051266.9A patent/CN102711740B/zh not_active Expired - Fee Related
- 2010-09-01 TR TR2012/05029T patent/TR201205029T1/xx unknown
- 2010-09-01 BR BR112012010325A patent/BR112012010325B8/pt not_active IP Right Cessation
- 2010-09-01 UA UAA201206606A patent/UA103558C2/ru unknown
- 2010-09-01 WO PCT/KR2010/005911 patent/WO2011052884A2/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060113728A (ko) * | 2003-11-13 | 2006-11-02 | 룀 게엠베하 | 조절 물질의 전달에 영향을 미치는 매트릭스를 갖는 다층약제학적 형태 |
KR20070017335A (ko) * | 2004-03-22 | 2007-02-09 | 노파르티스 아게 | 리카르바제핀을 포함하는 경구투여용 매트릭스 제제 |
KR20070119658A (ko) * | 2005-03-29 | 2007-12-20 | 에보니크 룀 게엠베하 | 활성 성분 방출에 대한 조절 효과를 가지는 물질을포함하는 펠렛을 포함하는 다중 미립자 제약 형태 |
KR20070078625A (ko) * | 2006-01-27 | 2007-08-01 | 씨제이 주식회사 | 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20110048367A (ko) | 2011-05-11 |
CN102711740A (zh) | 2012-10-03 |
RU2012119070A (ru) | 2013-12-10 |
TR201205029T1 (tr) | 2012-09-21 |
WO2011052884A3 (ko) | 2011-07-14 |
BR112012010325A2 (pt) | 2016-03-29 |
BR112012010325B8 (pt) | 2021-05-25 |
UA103558C2 (ru) | 2013-10-25 |
CN102711740B (zh) | 2014-02-12 |
RU2506947C2 (ru) | 2014-02-20 |
BR112012010325B1 (pt) | 2021-01-26 |
KR101137467B1 (ko) | 2012-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101234940B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
KR101931195B1 (ko) | 올메사탄 메독소밀 및 로수바스타틴 또는 그의 염을 포함하는 약학 조성물 | |
KR101612931B1 (ko) | 1일 1회 투여로 약리학적 임상 효과를 제공하는 모사프리드 서방성 제제 | |
WO2012005500A2 (ko) | 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물 | |
TW550076B (en) | Sustained release formulations | |
KR100780553B1 (ko) | 메트포르민 서방정 및 그의 제조방법 | |
CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
WO2014058188A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
WO2020138791A2 (ko) | 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법 | |
WO2013133620A1 (en) | Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same | |
WO2012008675A1 (ko) | 트리메부틴 함유 서방성 정제 | |
WO2011052884A2 (ko) | 테오브로민 함유 서방성 정제 | |
WO2012141502A2 (ko) | 아세클로페낙 함유 방출제어형 정제 | |
WO2016137266A2 (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
WO2014142521A1 (ko) | 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법 | |
WO2019132833A1 (en) | The modified release combination comprising linagliptin and metformin | |
WO2012111961A2 (ko) | 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제 | |
WO2019004713A2 (ko) | 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법 | |
US20210299051A1 (en) | Pharmaceutical composition for amelioration of adverse side effects | |
WO2012111965A2 (ko) | 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제 | |
WO1999065491A1 (en) | Method of treatment | |
KR101199654B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
WO2022034944A1 (ko) | 제2형 당뇨병 치료용 복합제제 | |
KR20110008773A (ko) | 독소필린 함유 서방출형 미세정제 및 이의 제조방법 | |
KR20100102441A (ko) | 제어방출형 고혈압 치료제의 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080051266.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10826969 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012/05029 Country of ref document: TR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201206606 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012119070 Country of ref document: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10826969 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012010325 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012010325 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120502 |